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Abstract—The applicability of machine learning-based anal- 
ysis in the field of biomedical field has been very beneficial in 
determining the biological mechanism and validation for a wide 
range of biological scenarios. This approach is also gaining 
momentum in various stem cells research activities, specifically for 
stem cells characterization and differentiation pattern. The 
adoption of similar computational approaches to study and assess 
biosafety and bioefficacy risks of stem cells for clinical application 
is the next progression. In particular where tumorigenicity has 
been one of the major concerns in stem cells therapy. There are 
many factors influencing tumorigenicity in stem cells which may 
be difficult to capture under conventional laboratory settings. In 
addition, given the possible multifactorial etiology of 
tumorigenicity, defining a one-size-fits-all strategy to test such 
risk in stem cells might not be feasible and may compromise stem 
cells safety and effectiveness in therapy. Given the increase in 
biological datasets (which is no longer limited to genomic data) 
and the advancement of health informatics powered by state-of-
the-art machine learning algorithms, there exists a potential for 
practical application in biosafety and bioefficacy of stem cells 
therapy. Here, we identified relevant machine learning approaches 
and suggested protocols intended for stem cells research focusing 
on the possibility of its usage for stem cells biosafety and 
bioefficacy assessment. Ultimately, generating models that may 
assist healthcare professionals to make a better-informed decision 
in stem cell therapy. 
 
I. INTRODUCTION 
Stem cells are undifferentiated cells found in all multicel- 
lular organisms which possess a unique self-renewal ability and 
multi-potential differentiation [1-3]. Stem cells have been 
associated with the fields of regenerative medicine and tissue 
engineering with the goal to improve health and quality of life, 
especially patients with debilitating diseases. Stem cells can be 
divided into three categories: (1) embryonic stem cells (ESC) 
derived (ESC) from early-stage embryos; (2) adult stem cells 
(ASC) and (3) induced pluripotent stem cells (iPSC). These 
cells owe its regenerative capacity to its ability to migrate to the  
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injured part of the body, to divide and produce daughter cells, 
which have the ability to differentiate into other lineages of cells 
in order to repair the damaged tissue under appropriate 
conditions [4]. The ability for stem cells to induce regeneration 
can be influenced by culture condition and the type of 
secretomes released [5]. Stem cells have been studied and even 
applied for the treatment of various clinical conditions. 
However, there are risks which needed for further evaluation 
(before clinical application), such as miss-differentiation of 
cells, miss- targeting of cells, immune rejection and the biggest 
concern is genomic instability or tumor formation [6, 7].  
While the application of stem cells for treatment is on the 
rise, their overall quantity in the body is scarce. Generally, cell 
therapy protocols require hundreds of millions of MSC per 
treatment and this would require cell expansion in vitro for 
about 10 weeks before implantation [8]. In this regard, long-
term expansion or manipulation of stem cells may contribute to 
cellular senescence or even tumorigenesis in vitro, which may 
cause them to be non-viable for clinical usage. This has led to 
concerns of biosafety and bioefficacy of stem cells in clinical 
application [9, 10]. The aforementioned concerns are mainly 
due to poor understanding of stem cells biological mechanism, 
which has prevented it from being used widely in research in 
clinical application. Experimental approaches based on 
phenotypic and genotypic profiling are limited, whereby, they 
can also be expensive and time- consuming [11-13]. 
Furthermore, these approaches would also require subsequent 
validation assays to confirm its accuracy, which apart from the 
small sample size, can also lead to misinterpretation of data. 
The recent development in stem cells research has shown 
that machine learning application can be used to overcome 
some of these limitations, particularly in phenotypic profiling 
of stem cells [14, 15]. Other potential applications that could 
be explored are annotation of stem cell genome [16], 
predictions of protein binding, identification of specific 
markers [17] or key transcriptional factors of stem cells and 
characterization of stem cells transcriptional regulatory 
networks [18]. 
There are datasets generated from experiments to quantify 
molecular variables related to stem cells biosafety and bio- 
efficacy, such as the gene and proteins interactions. However, 
these datasets are complex with an intricate network of molec- 
ular interactions and analysis [19, 20]. To address this com- 
plexity, machine learning could provide next-level analyses
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that would allow better insights and the generation of new 
information for better biosafety and bioefficacy assessment 
[18]. As such, this would also allow medical practitioners to be 
better informed in offering personalized treatment to patients in 
stem cells therapy. A similar approach is seen in cancer 
research, whereby, machine learning has been widely applied in 
the identification and classification of cancer cells. Similar 
machine learning models and approaches can be applied in stem 
cells research [21-24] that could assist in accelerating the 
evaluation of safety and efficacy of stem cells. This could 
potentially bring stem cells to the forefront of personalized 
medicine. The current and future research trends in stem cells 
research are presented as an overview in Figure 1. In this review, 
the advantages and limitations of machine learning in stem cells 
research were presented, including on how next-generation 
machine learning methods could be used to expand our 
understanding of stem cells biology and their biosafety and 
bioefficacy risks. We anticipate that machine learning could 
have substantial impacts on stem cells research and therapy, 
providing a supporting tool in making a personalized clinical 




II. STEM CELLS BIOSAFETY AND BIOEFFICACY 
PROFILES 
In general, stem cells are unspecialized cells with self- 
renewal and differentiation (into specialized cell) abilities [25]. 
However, each type of stem cells has different characteristics, 
which are attributed by their origin, biological characteristics 
and functionality. The ESC cells are pluripotent stem cells 
originated from the inner mass of blastocyst of the embryo and 
can give rise to the entire body tissue organs except for placenta 
and umbilical cord [26-28]. Meanwhile, ASC cells are somatic 
cells-derived from a certain part of the adult body, which can 
only give rise to stem cell progeny of the original site [29] in 
which they are found. They are known to be multi-potent with 
limited differentiation capacity [30, 31]. Adult stem cells are 
also known as mesenchymal stem cells (MSCs) [32-35].  
[Fig. 1 about here.] 
The iPSCs are capable in giving rise to all kinds of cell types 
in the body but the difference is that iPSCs are reprogrammed 
stem cells, whereby, somatic or primary cells are biologically 
reprogrammed, giving rise to stem cells similar in 
characteristics as ESCs in culture [36-38]. Due to this 
technique, iPSCs have been widely used as it reduced the 
dependency on ESCs and ASCs, which are limited in the cell 
population. The iPSCs have been profoundly utilized not only 
for repair, replenishment and replace the damaged cell, tissue 
and organ but they have also been employed for drug-response 
therapy [39].  Due to the regenerative capacity of stem cells, 
they have been regarded as a powerful tool in regenerative 
medicine, particularly in the treatment of debilitating diseases. 
However, such potential and capability have given rise to other 
clinical concerns, such as adverse effects associated with  
 
 
biosafety and bioefficacy issues. These effects may not 
materialize immediately after receiving stem cell therapy. Post 
therapy monitoring may be difficult as there are no established 
pre- or post-parameters and further, there is no ‘one-size-fits-
all’ protocol to enable such monitoring procedure. To develop 
a stem cell-based therapy, we must first ensure the safety and 
efficacy of stem cells. High efficiency of stem cells is needed 
to have effective homing, engraftment and persistence in 
damaged tissues, which would enable a stable interaction 
between the transplanted and the injured tissues. This is 
important to maximize the therapeutic capacity of stem cells.  
Studies on biosafety and bioefficacy of stem cells have been 
carried out for many years. There have been few reports 
addressing the biosafety and bioefficacy profiles of stem cells 
[10, 40, 41], which showed the importance of addressing these 
issues. As of now, there is no standard or conclusive data that 
can be used to establish a proper protocol for biosafety and 
bioefficacy assessment. Further, any protocols and guidelines 
established would need to be internationally accepted and 
harmonized [42]. The proposed minimal criteria to define 
human mesenchymal stem cells (MSC) was established by the 
Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy (ISCT). These 
criteria are; 1) MSC must be plastic-adherent when cultured in 
standard culture conditions, 2) MSC must express CD105, 
CD73 and CD90 and lack in the expressions of CD45, CD34, 
CD14 or CD11b, CD79α or CD19 and HLA-DR surface 
molecules and 3) MSC must be able to differentiate to 
osteoblasts, adipocytes and chondroblasts in vitro [43].  
Since then, further investigations on stem cells 
characteristics were carried out, which can be (directly or 
indirectly) used to evaluate the biosafety and bioefficacy 
profiles of stem cells. With regards to adult stem cells (ASC) or 
MSC, studies have shown that these stem cells were reported to 
have low risks of tumorigenicity in long-term culture [4, 44] 
and low risks of abnormalities following long-term 
cryopreservation [45]. While there are no significant changes in 
stem cells differentiation ability, cryopreservation caused stem 
cells to appear less fibroblastic in appearance [46]. Long-term 
culture of stem cells was also reported to alter its stemness and 
differentiation ability [46, 47]. On the other hand, 
tumorigenicity risks of embryonic stem cells (ESC) and 
induced pluripotent stem cells (iPSC) have been reported, 
which pose a hurdle in stem cell therapy [48, 49]. Furthermore, 
the differences in cell microenvironment and culture conditions 
contributed by biophysical and biochemical cues can affect 
stem cells response, for example, cell culture in hypoxia [50-
53], use of serum [54] and fluid shear forces [55]. This evidence 
also showed that stem cells response is affected by both static 
and dynamic interventions. 
Despite the successful clinical application of stem cells, the 
sample size is rather small, which may not be sufficient to 
determine the safety and efficacy of the treatment. The 
application of human allogeneic adipose-derived MSC showed 
feasibility in a pediatric patient with no adverse effects of up to 
12 months following treatment [56]. While Lennmyr et al. [57] 







leukemia was successfully treated with allogeneic 
hematopoietic stem cell transplantation (alloHSCT) with an 
increased overall survival rate of more than 10% in 5 years 
[57]. Meanwhile, Schlenk et al. [58] evaluated alloHSCT 
among patients having acute myeloid leukemia (AML) 
showed a significant beneficial impact after treatment. 
Similarly, Cornelissen et al. [59] reported that AML patients 
that were treated using alloHSCT have a significant beneficial 
impact with the overall increased survival rate of 12% and was 
successfully validated using cytogenetic profiling. However, 
there have been variations in terms of treatment outcomes and 
responses, which can be due to multiple factors that can be 
difficult to ascertain. Examples of these factors include 
different donors [60], age of donors [61] and different culture 
protocol [62], which may contribute to non-standardized 
outcomes and potentially adverse effects in stem cells therapy 
that can be irreversible. This has made it difficult to assess and 
to establish a standardized protocol to evaluate the biosafety 
and bioefficacy risks of stem cells. Therefore, machine 
learning-based predictive analytical methods are desirable to 
accelerate the discovery of new stem cell markers for safety 
assessment and to forecast stem cell therapy efficacy in order 
to minimize the potential adverse effects and to maximize the 
success of treatment.  
 
III. LIMITATIONS IN STEM CELL THERAPY WHICH POSE 
EFFICACY AND SAFETY ISSUES 
Although suitable stem cells safety and efficacy profiles and 
assessment are still not well established, stem cells have been 
used for various disease treatments. Stem cell therapies have 
been applied for the treatment of anemia [63], multiple 
myeloma [64-66], arthritis [67, 68] and even stroke [69, 70]. 
Stem cells therapies have also been applied for blood-related 
cancers, whereby, patients have undergone allogeneic 
hematopoietic stem cell transplantation (alloHSCT) for 
thalassemia [71] and acute myeloid leukemia (AML) [72-75]. 
In some cases, determining post-treatment efficacy and safety 
of stem cell therapy may be restricted due to the difficulty in 
following up after treatment. It might also be due to stem cells' 
dynamic responses in different individual recipient and disease 
models, which lead to variations in the outcome of the 
treatment. In this regard, there have been reports addressing 
post-treatment complications of stem cells therapy within a 
year following the treatment.  
Rovo and Tichelli [76] reported cardiovascular 
complication risk following allogeneic hematopoietic stem 
cell transplantation leading to considerable morbidity and 
mortality, including patients having critical diseases, such as 
dyslipidemia, arterial hypertension, diabetes mellitus and 
kidney disease. There have been reports of undesired 
differentiation and malignant transformation [77] as well as 
the ability to promote tumor growth and metastases, which has 
been a major concern in stem cells therapy [78]. Patients who 
have undergone autologous stem cell transplantation (ASCT) 
for lymphoma have a significant risk of developing therapy-




myelodysplasia (t-AML/MDS) [81]. This may be attributed by 
the ASCT procedure that includes priming chemotherapy, total 
body irradiation and the extensive cellular proliferative, which 
occur during engraftment, leading to the development of t-
AML/MDS. Graft-Versus-Host Disease (GVHD) is another 
adverse effect that occurs following stem cell treatment [82-84], 
which can be overcome by the use of a mismatched allograft 
that necessitates T cell depletion. Surprisingly, a greater HLA 
mismatch was associated with a lower risk of GVHD [85]. The 
mismatched donor lymphocyte infusion (DLI) was specifically 
created for prophylactic treatment of T cell depleted 
mismatched allograft recipient [85].  
All of these stem cells donors and recipients’ responses may 
be important factors needed to be considered carefully. 
Biological assays and genetic molecular expression data 
profiling may be able to overcome such limitations and 
challenges, but they may be cost-prohibitive and time-
consuming. Antibiotic matching, biomarker details and 
signaling pathways are all essential information needed but may 
require subsequent validation assays for accuracy. In this 
regard, dependency on biological assays may lead to the 
misinterpretation of data, particularly in terms of the similarity 
in biomarkers and molecular signaling pathways of various 
microenvironment and disease models. Hence, machine 
learning-based characterization and classification profiling 
techniques may be able to capture the genotypic and phenotypic 
differences as well as the changes that occur in a shorter period 
with more accuracy in terms of safety and efficacy of the stem 
cells.  
 
IV. MACHINE LEARNING APPLICATION OPPORTUNITY IN STEM 
CELLS BIOSAFETY AND BIOEFFICACY EVALUATION 
Understanding stem cells behavioral response and changes 
have been mainly carried out through biological assays that 
employed time-consuming and laborious methods [86, 87]. 
Furthermore, just like any biomedical datasets, stem cells 
datasets are generally limited by sample size [88]. To increase 
data for analysis, some investigators used 3D printing to create 
bio-scaffolds to mimic the natural environment of stem cells, 
but this approach was not always successful, whereby, stem 
cells often migrated away from the printed scaffolds or 
locations. Hence, the analysis of stem cells’ intrinsic ability and 
response were not always accurate. To overcome this 
limitation, the machine learning approach to study stem cells’ 
complexity is gaining momentum, particularly on the aspect of 
molecular and genomic changes in pluripotent stem cells.  
Machine learning is a common method in data analytics for 
identification and recognition of patterns, which when applied 
to stem cell biology, will enable the discoveries of new insights 
with reasonable accuracy in a shorter amount of time. This 
approach would also be of advantage as stem cells are known 
to form predictable patterns in their natural environment as they 
mature into tissues. Such analytics are difficult to duplicate in 
the lab, costly to perform, laborious and time consuming to 
execute. For instance, Libby et al. [89] used extended cellular 






dynamics that enabled them to demonstrate morphogenic 
dynamics through a model-driven exploration of stem cells 
behaviors, which is a vital step in organ modelling [89]. 
Understanding that the individual stem cell is different even if 
they are genetically cloned has led to the Allen Cell Explorer 
produced by the Allen Institute for Cell Science in Seattle, 
USA. The Allen Cell Explorer, which complements various 
ongoing projects, is an online catalogue, including the 3D 
images of stem cells as well as the iPSC that were produced 
using deep learning analysis and cell lines altered with the 
gene-editing tool, CRISPR [90]. It is also a growing library 
that charts the uniqueness of single cells at DNA, RNA and 
protein levels [90]. This gives a more holistic and unbiased 
approach to predict and understand multiple aspects of cellular 
structure and behaviors.  
Although machine learning application in stem cells research 
is not a commonality at this stage, a proof-of-concept study has 
been presented previously [91]. Zhang et al. [91] employed 
machine learning and microscopic image analysis to identify 
iPS progenitor cells in their effort to understand the origin and 
underlying mechanism of iPSC particularly at the early stage of 
cell reprogramming, including the biomarkers involved. 
However, the proposed model by Zhang et al. [91] showed 
inconsistencies in their prediction with large fluctuation. The 
model can only predict iPS progenitor cells with a minimum 
precision of 52%. The model is incapable of handling 
additional iPSC features and phases to achieve higher accuracy 
of the prediction performance.  
Machine learning models have been applied in cancer 
diagnostics and prognostics [15, 92-94], whereby, similar 
predictions and interpretation models can be applied in 
understanding stem cells, specifically for its biosafety and 
bioefficacy evaluation. Similar machine learning techniques 
can be used in predicting and studying the dynamic changes of 
stem cells behavior in a particular environment, which should 
be directed towards understanding its impact on biosafety and 
bioefficacy for clinical application. The combination of the 
dataset from cancer research and stem cells research for various 
machine learning models should be considered as an approach 
in understanding stem cells behavior and interactions as well as 
the risks of developing adverse effects following therapy. 
 
1. Image-based Dataset for Machine Learning in Stem Cells 
Research 
The common workflow of image processing consists of the 
preparation of image input data, pre-processing, segmentation, 
feature extraction and classification steps. The microscopic 
image should be prepared by capturing the cell image from cells 
or tissue samples using the microscopic digital camera or 
software. Technical expertise for manual classification may be 
required for image labelling, especially for images that will be 
used for supervised training. For automated application, the 
microscopic images provided by authorized databases can be 
used for training and testing. For simple and efficient methods 
of segmentation and feature extraction steps, techniques such 
as Convolutional Neural Networks (CNN), K-Means and Mean  
 
 
 Shift should be adopted. The SVM, Naive Bayes and Fully 
Convolutional Neural Network (FCNN) are among the 
techniques that have been used for cancer cell classification, 
which has the potential to be applied in stem cell research. 
Image processing or analysis has been beneficial in cancer 
research. Computer vision software based on machine learning 
and deep learning algorithms is making automated analysis 
possible in delivering fast and accurate results. In this regard, 
image processing plays a crucial role in the diagnosis and 
detection of cancers as well as in monitoring cancer progression 
patients [23].  
Similarly, machine learning is capable in overcoming 
limitations in stem cells research, whereby, lab-based 
characterization and classification using chemical reagents and 
biological assays can be labor-intensive, expensive, and time-
consuming as well as less accurate. Most implementations of 
supervised machine learning relied on extensive training data 
using extracts from large and high-throughput biological data 
and features, such as cellular images and genome analysis. 
From the perspectives of cancer diagnosis and stem cells 
therapy, the machine learning approach is useful to understand 
the regulatory genomics. This includes the identification of 
regulatory variants, the effects and origins of mutation using 
DNA sequence, analyzing whole cells, the population of cells 
and tissues through detecting features that can be difficult or 
impossible to uncover in conventional laboratory settings [95]. 
Pattern recognitions and classifications of such biological data 
are important in identifying factors, which pose biosafety and 
bioefficacy risks of stem cells in clinical application.  
While different techniques have been developed for analysis, 
deep learning method provide a more effective strategy due to 
the diversity of the data. It has been used to classify lesions and 
nodules; localize organs, regions, landmarks and lesions; 
segment organs, organ substructures and lesions; by retrieving 
images based on content; generating and enhancing images; and 
combining images with clinical reports [13, 96, 97]. The 
application of deep learning in analyzing images has been 
widely used in cancer stem cell phenotype research. Ke Fan et 
al. [98] demonstrated that the combination of SVM, RF and 
CNN was able to measure morphological dynamic and colony 
formation of iPSCs within 7 days.  The application of SVM by 
Tanaka et al. [99] enabled automated classification of 
adipogenic and osteogenic differentiation as well as 
undifferentiated features of human mesenchymal stem cells 
(hMSC) in RGB color image. Meanwhile, Theagarajan and Bir 
Bhanu [100] have developed and proposed new automated 
detection and classification of human embryonic stem cell 
(hESCs) with an accuracy of 94.46% using the application of 
CNN for phase contrast hESC image analysis.  
 
2. Stem Cells and Cancer Cells Feature Engineering for 
Machine Learning  
Several studies have shown that stem cells and cancer cells 
share some similarities. These similarities can be attributed to 
their functional capability that is conceptually similar in terms 





they are also fundamentally different, whereby, these cells can 
be distinguished by different regulatory mechanisms reflected 
in at least three characteristics; 1) propagation and 
proliferation ability, 2) morphology and 3) cell surface 
markers. These characteristics may be considered for risks 
evaluation associated with the safety and efficacy of stem 
cells. Image-based high-content screening has also become 
increasingly important in stem cells research in monitoring the 
changes in phenotype, such as cell morphology and 
differentiation [102, 103]. 
2.1. Proliferation and propagation ability 
In terms of proliferation ability, it is important to understand 
that normal stem cells are regularly more vigilance in 
controlling their proliferation, but this ability is lacking in 
cancer cells [101]. Cells population doubling time is one of the 
distinguishing factors that can be included as a feature used to 
train the machine learning model. However, it is important to 
also take into account the different models [101] used to 
understand cancer propagation. Cancer stem cells (CSCs) 
model is rare and is a phenotypically distinct group of cells, 
which may hierarchically induce the stable generation of non-
tumorigenic and tumorigenic cells. They can probably be 
generated from normal stem cells or precursor cells within 
tissues after mutations and resistant to conventional 
chemotherapy occurred [104].  
Although they are rare, certain markers have been suggested 
for the identification of CSCs. In the clonal evolution model, 
cancer cells are distinctive in phenotypes with malignant 
potential and ability for disease propagation by undergoing 
additional genetic mutations. While in the interconversion 
model, cells can interconvert between being actively malignant 
and relatively quiescent, which is associated with the 
phenotypic differences between these cells. Although there are 
distinctive differences in the cells in each model, they are not 
mutually exclusive, whereby, tumorigenic cells are able to 
undergo further genetic and epigenetic alterations, depending 
on their microenvironment regardless of which model the cells 
follow [105]. Based on the propagation and proliferation 
ability, specifically associated biomarkers, cell count or 
numbers and time-period depicting cells population growth 
could be the features that can be included in the training models 
to distinguish the characteristics of normal stem cells and 
cancer-associated cells.    
2.2 Cell Morphology 
Morphologically, stem cells and cancer cells may show 
different cell features, which can be viewed microscopically 
(Figure 2). Microscopic images of cells are crucial to extract 
information for the machine learning models to distinguish the 
different features of normal stem cells and cancer cells based 
on their sizes and shapes. Generally, the appearance of normal 
stem cells is more consistent in their shapes and smaller in size 
while cancer cells can be abnormal and vary in shapes and 
sizes, which may be contributed by their heterogeneous nature. 
Although they may exhibit unique differences in their 
morphology, cell features, and motions require laboratory   
 
 
experimental approaches to create sample dataset prior to 
machine learning modeling. Based on a suitable model, the 
identification of cancer progenitor cells can be confirmed based 
on the morphology and motion pattern, which may be different 
from normal cells. 
Zhang et al. [91] used time-lapse microscopic images of iPS 
forming cells in early stage reprogramming and selected 11 
types of cell morphological and motion features, which 
included the area of coverage and speed for modelling to 
perform feature selection. Further analysis of cell motion 
showed that migratory motions for progenitor cells can be 
distinguished by the direction and distance to bring distant 
progenitor cells together. However, the input of cell features 
described by Zhang et al. [91] and Meygola et al. [106] would 
require high-resolution time-lapse imaging to allow the 
detection or tracing of cellular events. With regards to cell 
segmentation and tracking, Dzyubachyk et al. [107] used 
coupled active surfaces algorithm and time-lapse fluorescence 
microscopy images. While Türetken et al. [108] proposed an 
integer programming to track elliptical cell populations in time-
lapse image sequences. In the case of image segmentation, the 
challenge with live-cell imaging is in determining which parts 
of images correspond to which individual cells. Van Valen et 
al. [83] showed that this can be solved by applying CNN that 
can robustly segment fluorescent images of cell nuclei and 
phase contrast images of cells without the use of a fluorescent 
cytoplasmic marker.  
 
[Fig. 2 about here.] 
 
2.3. Cell surface markers 
Cell surface markers are associated with features and changes 
in cell morphology and progression. Some require deep 
epigenetic experimental approaches for input. It is challenging 
in determining specific markers for normal stem cells, cancer 
cells or CSCs as most of these markers can be presented in all 
types of cells, making them non-specific. Otherwise, these 
aspects would require machine learning approach in identifying 
specific cell surface markers. In comparing between normal 
stem cells and cancer cell progression, it is mostly discussed 
within the context of CSCs, as stem cells have also been shown 
to be involved not just in cancer initiation and progression but 
also in CSCs generation [109]. Nevertheless, contradictory 
results on CSCs and stem cells relationships are still very much 
debatable.  
Although both cells share some similarities in terms of self-
renewal and differentiation ability, there are studies Some 
studies showed different characteristics between the two cell 
types and this can be delineated by the existence of specific cell 
markers [101, 110]. This feature can be used for machine 
learning approach to classify and track stem cells progression 
in a particular environment for the risks of them conforming or 
inclining towards cancer-associated cells. An important 
attribute of CSCs is that they have the ability to trans-
differentiate into different phenotypes [111, 112], whereby, 







be able to organize a pseudo vascular network. Several studies 
have also associated these characteristics to the expression of 
potentially CSC markers in several types of cancer cell lines, 
such as breast cancer cell lines, MDA-MB 453 and MDA-MB 
231 [113-115], non-small cell lung cancers (NSCLCs) [116], 
renal cell carcinoma Cell [117], nasopharyngeal carcinoma 
cell (NPC) [118], colon cancer cells mucoepidermoid 
carcinoma cell lines (YD15) and its derivative (YD15M) 
[119]. From these studies, it can be summarized that the 
characteristics of malignancy and cancer progression were 
typically associated with a panel of surface markers, which are 
𝐶𝐷133+, 𝐶𝐷44+, 𝐶𝐷24−, 𝑂𝐶𝑇3/4 , or/and 𝑁𝐴𝑁𝑂𝐺 [120, 
121]. On the other hand, the 
𝐶𝐷44ℎ𝑖𝑔ℎ  𝐸𝑆𝐴𝑙𝑜𝑤𝑒𝑟  or 𝐶𝐷44ℎ𝑖𝑔ℎ𝐸𝑆𝐴 ℎ𝑖𝑔ℎ expressions 
indicated the presence of CSCs population in squamous cell 
carcinoma in breast through a comprehensive analysis of data 
obtained from flow cytometry, immunohistochemical and real-
time polymerase chain reaction (RT-PCR) [112]. 
   Surface markers regulation leading to the induction of 
epithelial-mesenchymal transition (EMT), which resulted in 
the acquisition of invasive and metastatic properties is also one 
of the characteristics found in CSCs [119, 122]. EMT 
phenomenon in CSCs has been reported as metastasis 
precursor, which enable the cells to acquire invasiveness and 
become extremely resistant to conventional therapies [112, 
117]. The down-regulation of E-cadherin and upregulation of 
N-cadherin, which are termed as cadherin switching cascade, 
is a major hallmark of EMT. The cells which are undergoing 
EMT can be accurately identified through intensive genomic 
profiling for downregulation of cytokeratin (CK) and 
upregulation of vimentin, N-cadherin and fibronectin. This 
may be important markers for the characterization and 
identification of CSCs [119]. 
Currently, image analysis has been employed in the study of 
stem cells reprogramming and its progression using iPSCs. 
Kusumoto et al. [123] employed CNN   to identify endothelial 
cells derived from iPSCs, whereby, the networks were trained 
using phase contrast images of endothelial cells based on 
morphology only. The network performance was then 
assessed by K-fold cross-validation, which confirmed that 
CNN was able to identify endothelial cells based on 
morphology with high performance. On the other hand, 
computer vision-based deep learning was also used to study 
the progress of stem cells differentiation. CNN was also able 
to be trained with transmitted light microscopy images to 
identify pluripotent stem cells from early differentiating cells 
and its ability to recognize the features with more than 99% 
accuracy [124]. Similarly, the classification of light 
microscopic images was used to predict lineage choice and 
cellular movement of primary hematopoietic progenitors 
during differentiation [125].  
Despite limited machine learning application for stem cell 
biosafety and bioefficacy, comparative and classification 
analysis of stem cells can be carried out by comparing the cell 
images of stem cells and cancer cells without having the 
dependency on molecular and biological assays. Depending on 
a particular niche (i.e., whether in vitro or in vivo conditions), 




characteristics. This has been demonstrated in glioblastoma 
multiforme study by Adamski et al. [126], which reported that, 
there is a putative link between cellular dormancy of 
malignancies and stem cell-like characteristics in cancer that 
could be due to the co-expression stem cells markers. Based on  
these studies, the prediction in the risks of stem cells to acquire 
cancer characteristics prior to clinical applications is possible. 
 
 
V. TECHNICAL RECOMMENDATION OF MACHINE LEARNING IN 
STEM CELLS RESEARCH 
Machine learning classification techniques have been applied 
in cancer research to identify and classify the types of cancer 
cells with relatively high accuracy, sensitivity and specificity. 
Some popular applications involved Support Vector Machine 
(SVM), K-Nearest Neighbors (KNNs), Artificial Neural 
Networks (ANNs), Decision Tree (DT), Random Forest (RF) 
and Bayesian Networks (BNs) [121, 122, 127-131]. In addition 
to cancer, the classification of microscopic red blood cells 
images from hematological disorder, such as sickle cell disease 
using deep-CNNs were able to reveal a diverse and any 
alteration in the cell shapes related to their biomechanical and 
bio-rheological characteristics. The deep-CNN employed 
showed good performance, high accuracy and robust 
predictions that enabled clinicians to assess the severity of the 
disease [132]. Similar techniques can be used to assess or 
profile stem cells biosafety and bioefficacy based on image 
analysis.  
 
[Fig. 3 about here.] 
With regards to image analysis, there are typical preliminary 
steps of image processing techniques. The process consists of 
input image data, image pre-processing, image segmentation, 
feature extraction and classification steps (Figure 3). The 
microscopic data is commonly used as an input for the training. 
Segmentation is a critical step that ensures the success of all 
subsequent algorithm steps. This entire approach of 
segmentation can be divided into three steps: image pre-
processing, image segmentation and features extraction. In 
image pre-processing, the process commonly starts with the 
selection of sub-image or panel (usually nuclei or cell). The 
RGB color components and grayscale analysis will then be 
performed for sub-image or panel to find the contrast among the 
sub-image objects. The contrast level of RGB components is 
shown by the colored histogram.  
The further segmentation process will then be performed to 
the sub-images by doing image refining, filling and splitting 
processes to identify the region of interest of the respective sub- 
images. Features such as size, shape and texture can then be 
extracted according to the calculation on the region of interest. 
By comparison, between Mean Shifts segmentation [131] and 
K-Means segmentation [132], the K-Means technique is one of 
the most popular method as it is simple, fast and efficient. 
Technically, K-means makes two broad assumptions, whereby, 
the number of clusters is already known. K-means is fast and 






clusters, n is the number of points and T is the number of 
iterations [133]. The results of segmentation can then be used 
for the classification process to differentiate between the 
normal and abnormal cell. The typical process of image 
processing shown in Figure 3 has been commonly used in most 
nuclei-based cancer image processing. For example, by 
applying deep learning, patterns from several types of data, 
such as from cancer cell dataset and stem cells dataset can be 
automatically extracted [133]. This includes the detection, 
segmentation and recognition of cell images that can be used 
to predict the risk of cell irregularities that could jeopardize 
stem cells clinical application. The detection of cell 
irregularities is a multistage process, which also includes pre-
processing tasks, such as segmentation and feature extraction 
from microscopic cell images before the application of CNN 
[134]. This approach can be used to observe and evaluate stem 
cells progression, particularly during the expansion phase to 
detect and predict the risk of abnormalities prior to clinical 
application. The expansion of cells is required to increase the 
number of cells to ensure sufficient cells can be used in stem 
cells therapy. It is a cell manipulation procedure, whereby, 
technical manipulation can increase the possibility of 
genotypic and phenotypic alterations [135].  
Naik & Dixit [134] reported detailed technical steps in 
detecting cancer from microscopic biopsy images, comprising 
of the training and testing of the algorithm model. The machine 
learning architecture of cancer detection by Naik & Dixit [134] 
is shown in Figure 4. For both training and testing tasks, the 
sequence of step started by taking image samples using a 
microscope, followed by the segmentation and features 
extraction step using the CNN based image processing and 
finalized by a classification step using the Naive Bayes 
Algorithm. By using the CNN based image processing, the 
microscopic image that contains nuclei, cytoplasm and other 
features are segmented into 12 smaller bricks. In each 
segmented brick, the CNN based interpretation on types of 
cancer was done according to the features of grey level, color, 
texture, Law’s Texture Energy (LTE), wavelet and Tamura’s 
features. This interpretation, which was given in percentage, 
was then subjected to Naive Bayes algorithm to classify 
whether the image indicates the cells to be cancerous or not. In 
this regard, the CNN algorithm may be applied as the basic 
principle of deep learning-based cell identification. As 
reported by Kusumoto et al. [123], the deep learning 
identification is more straightforward and achieves higher 
accuracies compared to the other machine learning techniques 
without the requirement of image labelling. The technical steps 
implemented by Naik & Dixit [134] can be adopted for the 
detection and evaluation of stem cells biosafety and 
bioefficacy risks.  
 
[Fig. 4 about here.] 
 
 
In cancer research, the focus on early detection is important to 
stop or slow down the progression of tumor growth.  Similar  
 
 
motivation can be applied in stem cells research, whereby, 
machine learning approach can be used to observe stem cell 
progression, especially during the expansion phase to evaluate 
the risk of biosafety and bioefficacy. To do this, there should be 
an automated identification system based on cell morphological 
images using the machine learning approach. With the 
enhancement technology of CNN and deep learning algorithm 
on cell image analysis, the nuclei-based analysis seems 
promising. The nuclei-based analysis has been used in cervical 
cancer and blood-related cancer screening. The images can be 
obtained or captured using a light microscope supported by a 
CCD camera in a standard size. These images can be included 
as a dataset, which can technically be classified into categories 
for labeling (such as normal, abnormal, healthy or unhealthy).  
These datasets can be applied for automated machine 
learning approach for abnormality evaluation of stem cells. 
Hussain et al. [136] has simultaneously conducted nuclei 
(nucleus) segmentation and classification from the cervical 
cancer morphological cell image using U-net architecture-
based fully convolutional neural network (FCN).  Figure 5 
shows the nuclei image processing and machine learning 
classification architecture by Hussain et al. [136]. They adopted 
the shape representation model based on auto-encoders which 
act as a network regularizer to increase the strength and 
robustness of the FCN. The U-net architecture-based FCN 
framework was able to predict the type of nucleus class either 
belonging to the normal or abnormal classes from the cervical 
cancer smear images. It worked by assigning pixel-wise labels 
to individual nuclei in a whole slide image, which enabled the 
identification of multiple nuclei belonging to the same or 
different class as individual distinct instances.  
 
[Fig. 5 about here.] 
Wang et al. [137] conducted the nuclei segmentation process 
on cervical cancer morphological cell image using Mean-Shift 
clustering algorithm. Figure 6 shows the nuclei image 
processing and machine learning classification architecture by 
Wang et al. [137]. The classification was carried out based on 
the shape and textural features of the segmented images. The 
color space and Gabor features were extracted from the 
segmented image and put together to obtain a better 
classification performance. The nuclei segmentation-based 
analysis was also conducted by Rawat et. al [138] on leukaemia 
morphological cell image based on the global thresholding and 
histogram equalization. The details of nuclei image processing 
and machine learning classification architecture are described 
in Figure 7. The normal and abnormal classes were classified 
using the support vector machine (SVM) classifier. On the other 
hand, Negm et. al [139] conducted the K-Means clustering-
based segmentation process on nucleus, cytoplasm and whole-
cell of leukaemia morphological cell image to classify the 
normal and abnormal classes based on the decision support 
system classification.  
 
[Fig. 6 about here.] 
[Fig. 7 about here.] 




Figure 8 shows the architecture of nuclei image processing 
and machine learning classification by Negm et al. [139]. As 
described in this figure, K-means clustering segmentation 
process started by segmenting the nuclei or whole cell and the 
images were classified by a representation of three-color 
components, RGB (red, green, blue). The histogram of the color 
components indicates the contrast of the images. The most 
contrasted images were selected for K-mean clustering 
segmentation step. The K-means clustering-based segmentation 
was performed by partitioning the pre-processed image into K-
mean clusters, classifying and grouping items into k groups (k 
is the number of pre-selected groups), minimizing the sum of 
squared distances between the items and the corresponding 
centroid used in grouping [140]. For example, if the grouping 
items are; background, other non-target cells and the cells to be 
extracted, thus, the K number is 3 (K1:  background, K2: other 
non-targeted cells and K3: cells to be extracted).  
Through the K-Means algorithm, the desired region of cells 
(nucleus, cytoplasm and whole-cell) can be separated from the 
unwanted region (background and other non-targeted cells). 
The segmented desired region can then proceed for features 
extraction step, which based on geometry, statistics, textures 
and size ratio. The analysis of these features was then 
performed to differentiate the regions for the classification step. 
Taken together, the techniques and algorithms used in cancer 
research are recommended to be used in stem cells research, 
particularly for biosafety and bioefficacy evaluation as 
summarized in Figure 9. Taking cues from the summary of the 
image processing pipeline in Figure 9, we proposed a 
framework-specific for biosafety and bioefficacy assessment, 
as depicted in Figure 10.  
Ideally, this framework will be applicable to identify stem cells 
abnormality, particularly during the cell expansion phase. 
Following the proven studies in the similar domain, supervised 
learning will be employed where images with known 
normality level will be used as a training data. By utilizing 
CNN based image processing algorithm, the image of stem 
cells from microscope was segmented into smaller sub-image 
of a single cell that contains nuclei, cytoplasm and other 
features. In each segmented sub-image, the CNN based 
interpretation on the type of stem cell normality can be carried 
out according to the cell and nuclei features as exemplified 
previously [134]. The recommended features that should be 
considered are size, shape, grey level, color, texture, Law’s 
Texture Energy (LTE), wavelet and Tamura’s features. The 
performance metric for the model will be based on the 
features’ percentage of stem cell from each single cell sub-
image that showed normal or abnormal conditions. The sum of 
average for each feature will then become a metric for the 
classification using various models, such as Naive Bayes, 
Decision Tree or Random Forest. The summary of current 
machine learning application in stem cell research and cancer 
cell research is shown in Table 1. 
 
 






[Fig. 9 about here.] 
[Fig. 10 about here.] 
 
VI. THE CHALLENGES AND FUTURE OF PERSPECTIVES 
In summary, the possibilities to adopt the aforementioned 
technical steps in stem cell research, particularly for risk 
evaluation in biosafety and bioefficacy are immense. The 
overlapping aspects of stem cell biology and cancer cell biology 
have led to the increase of large and highly complex datasets 
being generated from biological experiments from quantifying 
molecular variables, such as gene, protein and metabolites 
associated with different cancer and stem cells types. This has 
given insights into further understanding of the biological 
systems. Taken together, their involvement in disease 
progression and mechanism can be realized using machine 
learning and deep learning approaches. These approaches are 
able to address the complexity and heterogeneity of these 
datasets, providing new perspectives and generate novel 
hypotheses, particularly with regards to biosafety and 
bioefficacy risks and concerns in stem cells therapy.  However, 
just as in any biomedical datasets, some of the challenges 
identified that may occur in stem cells research datasets are; 1) 
data requirements, which require large, labeled data to make 
deep learning successful, 2) overfitting in data training may 
inaccurately reflect underlying relationships, particularly in the 
heterogenous dataset and 3) interpretability of deep learning 
models may require better interpreting methods of its output 
[97]. 
Although the size of these datasets is increasing, there is still 
a need for massive, large datasets to reach meaningful 
perspectives and outcomes. Just as any biological system, data 
from stem cells biology can be incredibly complex with 
thousands of variables from different facets of physiological 
conditions.  With suitable machine learning and deep learning 
models, we can assess the aspects of biosafety and bioefficacy 
of stem cells for clinical application. The generated model could 
also be used to identify fundamental design principles to create 
a suitable microenvironment for stem cells growth without 
jeopardizing their mortality and without altering their 
epigenetic components that may lead to cellular abnormality.  
However, to create such large and well-annotated datasets to 
study such complex network would require multi-omics 
datasets, which can be very expensive. 
One of the options that could be utilized to take on this 
challenge is to use imaging data and analysis to characterize 
morphological and phenotypic changes of stem cells. This 
could be carried out by comparing the data from cancer and 
stem cells in various conditions and environmental 
perturbations as well as coupling it with deep learning 
algorithms. The data obtained would present interesting input 
in addressing biosafety and bioefficacy risks in stem cells 
therapy.  
Nevertheless, we still have a long way to go to uncover and 
harnessing the potential of stem cells for therapy and to play a 







offer another attractive alternative in understanding stem cells 
biology as well as their biosafety and bioefficacy risks. With 
the emerging developments of machine learning application, 
there will be new interpretation in the model features (as 
proposed in the aforementioned sections in this review). The 
interpretation could give rise to new and meaningful inputs or 
predictions from stem cell biological perspectives, which will 
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FIGURE 1: An overview of the current research trend in stem cells research. Collection of datasets particularly on characterization of stem and cancer cells 
would enable machine learning approach to be applied in stem cells research and subsequently in stem cells therapy. 
 
                     
FIGURE 2: Representative images of human adult stem cells and selected cancer cell lines (10X magnification). A) ADSC (Human adipose-derived stem 
cells), B) MCF-7 (Human breast cancer cell line), C) HGT-1 (Human gastric cancer cell line), D) U937 (Human lymphoma cell line) and E) HEPG2 (Human liver 











FIGURE 4: The machine learning architecture of cancer detection process which can be applied in stem cells biosafety and bioefficacy assessment. 
Adapted from Naik & Dixit [134]. 
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FIGURE 5: Nuclei image processing and machine learning classification architecture using U-net architecture-based fully convolutional neural network 
(FCN). Reproduced from Hussain et al. [136] with permission. 
 
 
FIGURE 6: Nuclei image processing and machine learning classification architecture using mean-shift clustering algorithm. Reproduced from Wang et al. 
[137] with permission 
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FIGURE 7: Nuclei image processing and machine learning classification architecture using support vector machine (SVM) classifier module. Reproduced 































































FIGURE 8: Nuclei image processing and machine learning classification architecture using K-Means clustering-based segmentation. Reproduced from 
Negm et al. [139] with permission. 
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FIGURE 9: Overview of commonly used image processing-based machine learning techniques in cancer research which can be applied in stem cell 





FIGURE 10: Image processing machine learning architecture proposed for stem cells research particularly for biosafety and bioefficacy assessment using 
microscopy images of human adipose derived stem cells as an example. 
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A SUMMARY OF CURRENT MACHINE LEARNING APPLICATION IN STEM CELL RESEARCH AND CANCER RESEARCH. 
Ref. Type of Cell 
 
Task       Learning Method                      Feature Selection                                   Parameters 
 [91] iPSC Live-cell microscopic imaging 
dataset for iPS progenitor cells 
detection. 
 
XGBoost algorithm  
 
11 types of features are extracted (volume, area, 
sphericity, ellipsoid-prolate, ellipsoid-oblate, nucleus-
cytoplasm volume ratio, displacement, speed, 
Intensity-StdDev, Intensity-Max, Intensity-Min) 
using time window and two-step feature selection. 
 
XGBoost setting (learning rate = 0.01, 
n_estimators = 385, gamma = 0, and 5-Kfold 
cross validation).  
[98] iPSC Time-lapse bright field image 
analysis for iPS colony 
formation detection and 
prediction 
 
CNN for iPSC colonies 
recognition, HMM for growth 
curve modelling (Baum-Welch 
and Viterbi algorithms), and 
AlexNet algorithm as classifier. 
 
2 main types of features selected (Colony texture and 
area of growth) using the sliding window method 
with Autolevels (AL) algorithm, Gaussian filter 
(GFP) and Random Walker algorithm for dataset pre-
processing.  
Batch normalized layer training for AlexNet with 
manual human validation.   
 
[123] iPSC Phase contrast and 
immunofluorescence image 
analysis of differentiated 
endothelial cells  
LeNet and 
AlexNet algorithm 
2 types of feature selected (Differentiated feature of 




LeNet and AlexNet architectures are available in 
[123] (Figure 3). 
 
Training was conducted with stochastic gradient 
descent, learning rate = 0.01, and cross-entropy 
error as loss function. 
 
Weight initialization using Xazier algorithm with 




Human ESC Phase contrast microscopic 
ESC images classification 
DeephESC 2.0 algorithm 
consisting of CNN, Triplet CNNs 
and Fused CNN-Triplet.  
6 types of features selected (cell clusters, debris, 
unattached cells, attached cells, dynamically blebbing 
cells and apoptically blebbing cells) following the 
image pre-processing with intensity modeling of a 
mixture of two Gaussians. 
 
Generative Multi Adversarial Networks (GMAN) is 
implemented for synthetic hESC images dataset. 
DeephESC 2.0 setting (learning rate = 1.2x10-2, 
momentum = 0.9 and weight decay = 1x10-3), 
variation of architectures to improve hESC 
classification is available in [100] (Table 4). 
 
Two triplets CNN were introduced to perform 
fine-grained classification using the architecture 
presented in Figure 9 [100] with hyper-
parameters setting in Table 6. 
 
GMAN discriminators setting is available in 
Table 7 [100]. 
  
[99] MSC Microphotograph of MSC 
image for differentiation 
analysis 
 
SVM algorithm 3 main types of features selected (Adipogenic 
differentiation, osteogenic differentiation and non-
differentiated) based on the intensity balance of RGB 
channels. 
 
RGB pixel intensities with maximum value of R 
= 255, G = 255, and B = 255. 
[107] Mouse ESC Time-lapse fluorescence 
microscopic image analysis of 
cell foci and cell motion 
Level-set-based cell segmentation 
and tracking algorithm  
1 type of feature selected (time course in cell phase 
transition) using cell segmentation and tracking with 
cell motion correction and foci segmentation and 
pattern recognition. 
Level-set-based cell segmentation and tracking 
hyperparameters (motion compensation 
algorithm, α = 0.5 and β = 0.95; λ of the 
smoothness energy term of the foci segmentation 
algorithm = 10%; focus size = 3-5 voxels; 
expected contrast = 0.05 & 0.2; cell-phase 
classification threshold = 30% of foci at 
boundary) 
[129] Breast cancer  Digital mammography images 
classification 
 
CNN algorithm (fully connected 
(FC) layers involving VGG 
network or Resnet network as 
8 types of feature selected (regional area, major axis 
length, mean intensity, background, malignant mass, 
benign mass, malignant calcification and benign 
CNN setting (First step with 3 training strategy: 
learning rate = 10-3, 10-4, 10-5. Second step with 2 
training strategy: learning rate = to 10−4; weight 
FIGURES 4 
 
patch classifier layers).  
 
The complete network design is 
presented in Figure 1 [129]. 
  
calcification). decay = 0.001 and learning rate to 10−5; weight 
decay = 0.01) 
 
[134] Breast cancer  Magnetic Resonance Images 
(MRI) dataset classification 
CNN algorithm for image 
processing and Naïve Bayes as 
classifier 
4 types of colour-based feature selected (grey-level 
texture feature, Law’s Texture energy, Tamura 





Pap smear images 
classification 
FCN algorithm with U-net variant 
comprising of residual blocks 
from Deep Residual Networks 
and dense blocks from Densely 
Connected Networks within the 
shape representation model 
(SRM) encoder. 
  
3 types of feature selected (cell nuclei irregularity 
size, shape and texture). 
 
Stacked auto-encoder (SAE) is implemented to 
construct SRM for segmentation. 
  
FCN network architecture is presented in Figure 
4 [136]. Optimization of the network was 
performed with Adam optimizer. 
 
FCN algorithm hyperparameters (stochastic 
gradient descent, learning rate = 0.01; reduced by 
a factor of 10 every 5 epochs, and momentum = 




Pap smear images 
classification 
SVM algorithm as classifier and 
Mean-shift clustering algorithm 




5 types of selected features (cell nuclei area, 
perimeter, eccentricity, roundness, circularity) 
 
Optimal feature set is obtained using chain-like agent 
genetic algorithm (CAGA), P-value and maximum 








Microscopic blood images 
classification 
Genetic algorithm (GA) for 
feature selection with SVM 
algorithm as classifier. 
3 main types of selected features (colour, statistical 
texture & geometric - area, perimeter, diameter, 
Euler's no, major axis, minor axis, solidity, 
eccentricity, roundness, convex area and extent). 
 
The complete list of the extracted features and 
methods for extraction is available in Table 6 [138]. 
GA setting (size population = 20, number of 
generations = 10, replacement rate = 0.8, 
crossover fraction = 0.5, mutation fraction = 
0.01, fitness scaling = rank, selection function = 
roulette, no of variables = 331), 
SVM hyperparameters (Gamma g = 0.0057/κ, 
Cost C = 15,334). 
 
Various kernel functions and hyperparameters 
configuration were experimented. Details of the 
recommended configurations are available in 
Table 15, with details analysis in Table 8 - 14 
[138]. 
 
[139] Leukaemia Acute leukemia blast cells in 
colored microscopic images 
classification  
 
Artificial Neural Network (ANN) 
and Decision Tree as classifier 
with K-means clustering 
algorithm  
4 main types of selected features (geometry, statistics, 
textures, and size ratio from selected regions in 
nucleus, cytoplasm and whole cell)  
N/A 
Notes; iPSC-induced Pluripotent Stem Cells, MSC-Mesenchymal Stem Cells, ESC-Embryonic Stem Cells, Min-Minimum, Max-Maximum 
 
 
 
 
 
